SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sanofi India informs about disclosure

24 Apr 2025 Evaluate
In compliance with Regulation 30 of the SEBI (LODR) Regulations, Sanofi India has submitted the disclosure regarding Order issued by the Commissioner Central GST & Central Excise, Vadodara II. The matter was remanded by CESTAT to the commissioner for examination regarding the reversal of CENVAT credit. Following the remand, the commissioner confirmed the demand of Rs. 5,25,70,852 along with an equivalent penalty. While the matter was reconsidered, the commissioner proceeded to confirm the demand and penalty as stated.

The above information is a part of company’s filings submitted to BSE.

Sanofi India Share Price

3287.60 -40.25 (-1.21%)
11-May-2026 12:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1874.20
Dr. Reddys Lab 1295.65
Cipla 1314.50
Zydus Lifesciences 943.65
Lupin 2267.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×